Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM +0.36%34 EBITDA Margin % is 52.28% as of Mar. 2026, which is 15% above its 10-year median of 45.42. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Anthem Biosciences ranks better than 93.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anthem Biosciences's EBITDA for the
three
months ended in Mar. 2026 was ₹3,194 Mil. Anthem Biosciences's Revenue for the
three
months ended in Mar. 2026 was ₹6,109 Mil. Therefore, Anthem Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was 52.28%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anthem Biosciences EBITDA Margin % Related Terms
Anthem Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ANTHEM vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Anthem Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthem Biosciences (NSE:ANTHEM) has a EBITDA Margin % of 52.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anthem Biosciences and its competitors. This is 15% above median its historical median of 45.42. Over the past decade, Anthem Biosciences' EBITDA Margin % has ranged from 40.05 to 53.86. According to the industry distribution chart, Anthem Biosciences ranks #63 out of 939 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Anthem Biosciences' EBITDA Margin % too high?
Anthem Biosciences' current EBITDA Margin % of 52.28% is 15% above median its 10-year median of 45.42. Over the past 10 years, this metric has ranged from a low of 40.05 to a high of 53.86. Based on the distribution chart, Anthem Biosciences ranks #63 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #63 out of 939 companies for EBITDA Margin %. This places Anthem Biosciences in the top 7% of its industry — outperforming the majority of peers. Historically, Anthem Biosciences' own EBITDA Margin % has ranged from 40.05 to 53.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current EBITDA Margin % is 52.28%, which is 15% above median its own 10-year median of 45.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current EBITDA Margin % of 52.28%. The current EBITDA Margin % is 52.28%, which is 15% above median its 10-year median of 45.42. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current EBITDA Margin % is 52.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score
Get the complete analysis for NSE:ANTHEM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
